Home > In process > Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit | Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease > print

001     284032
005     20260119111814.0
024 7 _ |a 10.1007/s00115-025-01839-1
|2 doi
024 7 _ |a pmid:40548968
|2 pmid
024 7 _ |a 0028-2804
|2 ISSN
024 7 _ |a 1433-0407
|2 ISSN
037 _ _ |a DZNE-2026-00075
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Müller, Daniel J
|0 P:(DE-2719)2811675
|b 0
245 _ _ |a Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit | Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease
260 _ _ |a Heidelberg
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768817783_6719
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ApoE-genotype
|2 Other
650 _ 7 |a Adverse effects
|2 Other
650 _ 7 |a Alzheimer disease
|2 Other
650 _ 7 |a Lecanemab
|2 Other
650 _ 7 |a Medication safety
|2 Other
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Apolipoproteins E
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: adverse effects
|2 MeSH
650 _ 2 |a Genetic Testing: methods
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease: genetics
|2 MeSH
650 _ 2 |a Apolipoproteins E: genetics
|2 MeSH
700 1 _ |a Freitag, Christine M
|b 1
700 1 _ |a Heilbronner, Urs
|b 2
700 1 _ |a Nöthen, Markus M
|0 P:(DE-2719)9000400
|b 3
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 4
|u dzne
700 1 _ |a Rietschel, Marcella
|b 5
700 1 _ |a Schulte, Eva C
|b 6
700 1 _ |a Deckert, Jürgen
|b 7
700 1 _ |a Referat Genetische, molekulare und zelluläre Neurowissenschaften der DGPPN
|b 8
|e Collaboration Author
773 _ _ |a 10.1007/s00115-025-01839-1
|g Vol. 97, no. 1, p. 82 - 85
|0 PERI:(DE-600)1462945-8
|n 1
|p 82 - 85
|t Der Nervenarzt
|v 97
|y 2026
|x 0028-2804
856 4 _ |u https://pub.dzne.de/record/284032/files/DZNE-2026-00075_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/284032/files/DZNE-2026-00075_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812234
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NERVENARZT : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21